|
|
||||||||
1Department of Physiology, Queen's University, Kingston, Ontario and 2Department of Biochemistry, University of Western Ontario, Siebens-Drake Research Institute, London, Ontario, Canada; and 3The Children's Hospital and Research Foundation, Division of Molecular and Cardiovascular Biology, Cincinnati, Ohio; and 4Department of Biochemistry, Queen's University, Kingston, Ontario, Canada
Submitted 12 October 2004 ; accepted in final form 13 July 2005
A two-dimensional gel electrophoresis (2-DE)-based proteomic approach was used to study a transgenic mouse model of acerbated dilated cardiomyopathy in which the small monomeric GTPase, Rac1, was constitutively expressed exclusively in the myocardium. A subfractionation procedure allowed for the focused analysis of both cytoplasmic and myofilament protein-enriched extracts of ventricular tissue from Rac1 transgenic and age-matched nontransgenic (NTG) mice. The majority of these mice displayed severe hypertrophy (heart-to-body weight ratios >2-fold greater in the Rac1 mice) and died from overt heart failure between days 14 and 17. Comparative 2-DE analysis (pH 310, 12% SDS-PAGE) derived from Rac1 (n = 4) and NTG (n = 4) groups revealed differences in mean protein spot intensities. Twelve proteins from the cytoplasmic protein-enriched extract met our criteria for robustness and spot resolution and were identified. These proteins represent a broad distribution of cellular functions with only some previously implicated in myocardial hypertrophy. The myofilament subproteome displayed no change in posttranslational modification, but further analysis by one-dimensional Western blot showed increased quantities of myofilament proteins in the Rac1 mouse ventricles. Additionally, three proteins with different functionality that were altered in the cytoplasmic protein-enriched subproteome, tubulin
-chain, manganese superoxide dismutase, and malate dehydrogenase, were analyzed at days 7, 9, and 11 to assess their role in the development of the dilated cardiomyopathic phenotype. The quantity of all three proteins peaked at day 9, suggesting an early response in cardiac hypertrophic failure.
dilated cardiomyopathy; two-dimensional gel electrophoresis; mass spectrometry
This article has been cited by other articles:
![]() |
A. V. G. Edwards, M. Y. White, and S. J. Cordwell The Role of Proteomics in Clinical Cardiovascular Biomarker Discovery Mol. Cell. Proteomics, October 1, 2008; 7(10): 1824 - 1837. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Arab, A. O. Gramolini, P. Ping, T. Kislinger, B. Stanley, J. van Eyk, M. Ouzounian, D. H. MacLennan, A. Emili, and P. P. Liu Cardiovascular Proteomics: Tools to Develop Novel Biomarkers and Potential Applications J. Am. Coll. Cardiol., November 7, 2006; 48(9): 1733 - 1741. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Brown, D. P. Del Re, and M. A. Sussman The Rac and Rho Hall of Fame: A Decade of Hypertrophic Signaling Hits Circ. Res., March 31, 2006; 98(6): 730 - 742. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |